TAB. TIGADAC-90 (Ticagrelor 90 mg) BLISTER 10 X 10 by Daksh Diabetic & Cardiac Care, ISO certified pharmaceutical company in India, WHO-GMP pharma manufacturer, third party pharmaceutical manufacturing India, pharmaceutical marketing company India, diabetic care pharmaceutical products India, cardiac care pharmaceutical products India, anti-hypertensive drugs manufacturer India, cholesterol-lowering medications India, oral antidiabetic drugs manufacturer, insulin products India, blood sugar monitoring devices, heart failure treatments pharma, preventive cardiac supplements, pharma franchise company India, Panchkula Haryana pharma company, trusted Indian pharma manufacturer.
TAB. TIGADAC-90 (Ticagrelor 90 mg) BLISTER 10 X 10 by Daksh Diabetic & Cardiac Care, ISO certified pharmaceutical company in India, WHO-GMP pharma manufacturer, third party pharmaceutical manufacturing India, pharmaceutical marketing company India, diabetic care pharmaceutical products India, cardiac care pharmaceutical products India, anti-hypertensive drugs manufacturer India, cholesterol-lowering medications India, oral antidiabetic drugs manufacturer, insulin products India, blood sugar monitoring devices, heart failure treatments pharma, preventive cardiac supplements, pharma franchise company India, Panchkula Haryana pharma company, trusted Indian pharma manufacturer.
TAB. TIGADAC-90 (Ticagrelor 90 mg) BLISTER 10 X 10 by Daksh Diabetic & Cardiac Care, ISO certified pharmaceutical company in India, WHO-GMP pharma manufacturer, third party pharmaceutical manufacturing India, pharmaceutical marketing company India, diabetic care pharmaceutical products India, cardiac care pharmaceutical products India, anti-hypertensive drugs manufacturer India, cholesterol-lowering medications India, oral antidiabetic drugs manufacturer, insulin products India, blood sugar monitoring devices, heart failure treatments pharma, preventive cardiac supplements, pharma franchise company India, Panchkula Haryana pharma company, trusted Indian pharma manufacturer.
TAB. TIGADAC-90 (Ticagrelor 90 mg) BLISTER 10 X 10 by Daksh Diabetic & Cardiac Care, ISO certified pharmaceutical company in India, WHO-GMP pharma manufacturer, third party pharmaceutical manufacturing India, pharmaceutical marketing company India, diabetic care pharmaceutical products India, cardiac care pharmaceutical products India, anti-hypertensive drugs manufacturer India, cholesterol-lowering medications India, oral antidiabetic drugs manufacturer, insulin products India, blood sugar monitoring devices, heart failure treatments pharma, preventive cardiac supplements, pharma franchise company India, Panchkula Haryana pharma company, trusted Indian pharma manufacturer.

TIGADAC

TAB. TIGADAC-90 Ticagrelor 90 mg BLISTER 10 X 10
Category: Tag:
Send Enquiry

Introduction:
The TIGADAC product line is a trusted range of antiplatelet therapy featuring Ticagrelor 90 mg, a potent, reversible P2Y12 platelet aggregation inhibitor. Designed for the prevention of thrombotic events in patients with acute coronary syndrome (ACS), TIGADAC offers rapid onset, consistent platelet inhibition, and superior cardiovascular protection compared to older antiplatelet agents. With its unique reversible binding and twice-daily dosing, TIGADAC ensures reliable prevention of stent thrombosis, myocardial infarction, and cardiovascular death. Available in convenient blister packaging (10 x 10 tablets), TIGADAC guarantees quality, stability, and ease of dispensing.

Product Range & Benefits

TIGADAC-90

  • Composition: Ticagrelor 90 mg

  • Packaging: BLISTER, 10 x 10 Tablets

  • Use: Indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome (STEMI, NSTEMI, unstable angina), including those managed medically or undergoing percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).

Indications:

  • Acute coronary syndrome (STEMI and NSTEMI)

  • Prevention of myocardial infarction (MI)

  • Prevention of stent thrombosis (post-PCI)

  • Reduction of cardiovascular death in high-risk patients

  • Secondary prevention in patients with prior MI (past 1-2 years)

Dosage and Administration:

  • Loading dose: 180 mg (two 90 mg tablets) as a single dose at the time of diagnosis.

  • Maintenance dose: One tablet (90 mg) twice daily (approximately every 12 hours).

  • Continue therapy for up to 12 months, or as directed by physician.

  • May be taken with or without food.

  • Do not miss a dose; if a dose is missed, take it as soon as remembered and take the next dose at its scheduled time (do not double dose).

  • Dual antiplatelet therapy (DAPT) with low-dose aspirin (75-100 mg once daily) is standard.

Precautions & Warnings:

  • Contraindicated in active pathological bleeding (intracranial hemorrhage, GI bleeding), history of intracranial hemorrhage, and severe hepatic impairment.

  • Use cautiously in patients at risk of bleeding (recent trauma, surgery, gastrointestinal ulcers, coagulation disorders, concomitant anticoagulants).

  • Do not combine with high-dose aspirin (>100 mg) – reduces efficacy.

  • Avoid in patients with a history of bronchial asthma, COPD, or bradyarrhythmias (ticagrelor may cause dyspnea and ventricular pauses).

  • Discontinue 5 days before elective surgery or dental procedures (unless antiplatelet effect is required).

  • Not recommended for use in patients requiring urgent CABG.

Drug Interactions:

  • Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir): Contraindicated

  • Strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine): Contraindicated

  • CYP3A4 substrates with narrow therapeutic index (simvastatin, lovastatin): Avoid (use alternative statin like atorvastatin or rosuvastatin)

  • Digoxin: Monitor levels closely

  • Anticoagulants (warfarin, DOACs): Increased bleeding risk

Possible Side Effects:

  • Bleeding (most common): Epistaxis, gastrointestinal bleeding, bruising, hematuria, bleeding at puncture sites

  • Dyspnea (shortness of breath) – mild to moderate, usually transient

  • Headache, dizziness

  • Nausea, diarrhea, constipation

  • Ventricular pauses (usually asymptomatic)

  • Hyperuricemia, gout (rare)

  • Bradyarrhythmias

Conclusion:
TIGADAC-90 (Ticagrelor 90 mg) offers potent, predictable, and reversible antiplatelet therapy for patients with acute coronary syndrome and those at high risk of atherothrombotic events. With its rapid onset, superior efficacy over clopidogrel, and twice-daily convenience, TIGADAC is a trusted choice for preventing stent thrombosis, myocardial infarction, and cardiovascular death.

If you’re looking to buy Ticagrelor 90 mg tablets online or for clinical use, trust TIGADAC for proven antiplatelet efficacy, consistent quality, and reliable cardiovascular protection.

Note : Always Consult a physician before taking any medication, and do not rely solely on this information for medical advice.

For more such product information and similar product category Cardiac

You can also contact us  https://diabetes-cardiac.com/contact-us/

Related products